摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-cyclopentyl-1-[3-[(E)-2-(furan-2-yl)ethenyl]pyrazol-1-yl]ethanone | 1055927-90-6

中文名称
——
中文别名
——
英文名称
2-cyclopentyl-1-[3-[(E)-2-(furan-2-yl)ethenyl]pyrazol-1-yl]ethanone
英文别名
——
2-cyclopentyl-1-[3-[(E)-2-(furan-2-yl)ethenyl]pyrazol-1-yl]ethanone化学式
CAS
1055927-90-6
化学式
C16H18N2O2
mdl
——
分子量
270.331
InChiKey
LUEHDJJCNRCOJG-BQYQJAHWSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    20
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    48
  • 氢给体数:
    0
  • 氢受体数:
    3

文献信息

  • METHODS AND COMPOSITIONS OF SMALL MOLECULE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY
    申请人:Angion Biomedica Corp.
    公开号:US20180009793A1
    公开(公告)日:2018-01-11
    The present invention provides compositions and formulations of compounds having formula (I) and pharmaceutically acceptable derivatives thereof, wherein p, R 1 , R 2 and B are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of injuries, conditions or diseases in which HGF/SF or the activities thereof, or agonists or antagonists thereof have a therapeutically useful role. In addition, methods are provided for treating such diseases or diseases starting at a time after the onset of the injury, condition or disease.
    本发明提供具有公式(I)及其药学上可接受的衍生物的组合物和配方,其中p,R1,R2和B如本文中一般和在类和子类中所述,并提供其制药组合物以及使用它们治疗HGF/SF或其活性或其激动剂或拮抗剂在治疗中有治疗用途的任何损伤,疾病或疾病的方法。此外,还提供了治疗这些疾病或在损伤,疾病或疾病发病后的时间开始治疗的方法。
  • Small molecule modulators of hepatocyte growth factor (scatter factor) activity
    申请人:Zembower E. David
    公开号:US20080015243A1
    公开(公告)日:2008-01-17
    The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R 1 , R 2 and B are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases in which HGF/SF or the activities thereof, or agonists or antagonists thereof have a therapeutically useful role.
    本发明提供具有公式(I)的化合物及其药学上可接受的衍生物,其中R1、R2和B如本文中一般和在各类和亚类中所描述的,并且还提供了其制药组合物,以及使用它们治疗HGF/SF或其活性或其激动剂或拮抗剂在治疗中具有治疗用途的多种情况或疾病的方法。
  • HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES
    申请人:Paka Latha
    公开号:US20100256117A1
    公开(公告)日:2010-10-07
    Methods are provided for treating fibrotic connective tissue diseases such as scleroderma and conditions such as surgically-induced adhesions using compounds that activate the signaling pathways of hepatocyte growth factor.
  • HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN DEMYELINATING DISEASES AND CENTRAL NERVOUS SYSTEM TRAUMA
    申请人:Yuzhakov Alexander
    公开号:US20110230407A1
    公开(公告)日:2011-09-22
    Methods are provided for treating and preventing demyelinating diseases including multiple sclerosis, and traumatic injury to the central nervous system including brain trauma and spinal cord injury, by administering a compound or pharmaceutical composition of the invention. Useful compounds include hepatocyte growth factor/scatter factor protein, fragments, fusion polypeptides and muteins thereof, and nucleic acid and expression vectors encoding such proteins. Other useful compounds include small molecule HGF/SF agonists and mimetics.
  • METHODS OF USE OF SMALL MOLECULE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY
    申请人:Smith David E.
    公开号:US20130190376A1
    公开(公告)日:2013-07-25
    The present invention provides methods for treating a disease or condition by administering to a subject at a frequency of more than 24 hours between doses, compositions and formulations of compounds having formula (I), and pharmaceutically acceptable derivatives thereof, wherein p, R1, R2 and B are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of injuries, conditions or diseases in which HGF/SF or the activities thereof, or agonists or antagonists thereof have a therapeutically useful role.
查看更多